Generation and characterization of a monoclonal antibody that binds to Galectin-1

Kirsten Pfeffer; Thai H. Ho; Francisca J. Grill; Yvette Ruiz; Douglas F. Lake

doi:10.1016/j.pep.2023.106308

Generation and characterization of a monoclonal antibody that binds to Galectin-1

Kirsten Pfeffer, Thai H. Ho, Francisca J. Grill, Yvette Ruiz, Douglas F. Lake

Life Sciences, School of (SOLS)

Research output: Contribution to journal › Article › peer-review

Abstract

Galectin-1 is a β-galactoside-binding lectin that has been implicated as a suppressive molecule in cancer and autoimmune diseases. Gal-1 has known immunomodulatory activity and was found to be expressed on regulatory T cells, leading to the potential for targeted immunotherapies. Anti-Gal-1 monoclonal antibodies were generated in this study using classical hybridoma techniques. MAb 6F3 was found to bind to Gal-1 by Western blot and ELISA. Flow cytometry was used to determine cell surface and intracellular binding of mAb 6F3 to Gal-1 in PBMC-derived Tregs and tumor cells, including Treg-like cell lines. These results suggest mAb 6F3 may be used to further study Gal-1 protein expression and function.

Original language	English (US)
Article number	106308
Journal	Protein Expression and Purification
Volume	210
DOIs	https://doi.org/10.1016/j.pep.2023.106308
State	Published - Oct 2023

Keywords

Galectin-1
Immune suppression
Monoclonal antibody

ASJC Scopus subject areas

Biotechnology

Access to Document

10.1016/j.pep.2023.106308

Cite this

@article{d329e477e2b14030990e020b13b9b3ba,

title = "Generation and characterization of a monoclonal antibody that binds to Galectin-1",

abstract = "Galectin-1 is a β-galactoside-binding lectin that has been implicated as a suppressive molecule in cancer and autoimmune diseases. Gal-1 has known immunomodulatory activity and was found to be expressed on regulatory T cells, leading to the potential for targeted immunotherapies. Anti-Gal-1 monoclonal antibodies were generated in this study using classical hybridoma techniques. MAb 6F3 was found to bind to Gal-1 by Western blot and ELISA. Flow cytometry was used to determine cell surface and intracellular binding of mAb 6F3 to Gal-1 in PBMC-derived Tregs and tumor cells, including Treg-like cell lines. These results suggest mAb 6F3 may be used to further study Gal-1 protein expression and function.",

keywords = "Galectin-1, Immune suppression, Monoclonal antibody",

author = "Kirsten Pfeffer and Ho, {Thai H.} and Grill, {Francisca J.} and Yvette Ruiz and Lake, {Douglas F.}",

note = "Funding Information: This work was supported by NIH grants R01 CA224917 (THH) and CA271503 (THH). Funding Information: This work was supported by NIH grants R01 CA224917 (THH) and CA271503 (THH).THH has received research funding from Novartis and has served on advisory boards for Exelixis, Genentech, EMD-Serono, Ipsen, Cardinal Health, Surface Therapeutics, and Pfizer. The other authors declare no conflict of interest. Publisher Copyright: {\textcopyright} 2023 Elsevier Inc.",

year = "2023",

month = oct,

doi = "10.1016/j.pep.2023.106308",

language = "English (US)",

volume = "210",

journal = "Protein Expression and Purification",

issn = "1046-5928",

publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Generation and characterization of a monoclonal antibody that binds to Galectin-1

AU - Pfeffer, Kirsten

AU - Ho, Thai H.

AU - Grill, Francisca J.

AU - Ruiz, Yvette

AU - Lake, Douglas F.

N1 - Funding Information: This work was supported by NIH grants R01 CA224917 (THH) and CA271503 (THH). Funding Information: This work was supported by NIH grants R01 CA224917 (THH) and CA271503 (THH).THH has received research funding from Novartis and has served on advisory boards for Exelixis, Genentech, EMD-Serono, Ipsen, Cardinal Health, Surface Therapeutics, and Pfizer. The other authors declare no conflict of interest. Publisher Copyright: © 2023 Elsevier Inc.

PY - 2023/10

Y1 - 2023/10

N2 - Galectin-1 is a β-galactoside-binding lectin that has been implicated as a suppressive molecule in cancer and autoimmune diseases. Gal-1 has known immunomodulatory activity and was found to be expressed on regulatory T cells, leading to the potential for targeted immunotherapies. Anti-Gal-1 monoclonal antibodies were generated in this study using classical hybridoma techniques. MAb 6F3 was found to bind to Gal-1 by Western blot and ELISA. Flow cytometry was used to determine cell surface and intracellular binding of mAb 6F3 to Gal-1 in PBMC-derived Tregs and tumor cells, including Treg-like cell lines. These results suggest mAb 6F3 may be used to further study Gal-1 protein expression and function.

AB - Galectin-1 is a β-galactoside-binding lectin that has been implicated as a suppressive molecule in cancer and autoimmune diseases. Gal-1 has known immunomodulatory activity and was found to be expressed on regulatory T cells, leading to the potential for targeted immunotherapies. Anti-Gal-1 monoclonal antibodies were generated in this study using classical hybridoma techniques. MAb 6F3 was found to bind to Gal-1 by Western blot and ELISA. Flow cytometry was used to determine cell surface and intracellular binding of mAb 6F3 to Gal-1 in PBMC-derived Tregs and tumor cells, including Treg-like cell lines. These results suggest mAb 6F3 may be used to further study Gal-1 protein expression and function.

KW - Galectin-1

KW - Immune suppression

KW - Monoclonal antibody

UR - http://www.scopus.com/inward/record.url?scp=85159637236&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85159637236&partnerID=8YFLogxK

U2 - 10.1016/j.pep.2023.106308

DO - 10.1016/j.pep.2023.106308

M3 - Article

C2 - 37209931

AN - SCOPUS:85159637236

SN - 1046-5928

VL - 210

JO - Protein Expression and Purification

JF - Protein Expression and Purification

M1 - 106308

ER -

Generation and characterization of a monoclonal antibody that binds to Galectin-1

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this